StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil by Year

Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide sales ($M) ($M)

Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil: $306M in FY2025, up 22.9% from a year earlier.

Latest, FY2025
306
Period ended Dec 31, 2025
Change on a year earlier
+22.9%
249 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| Delstrigo | 75 | 101 | 176 | 67 | 83 | 150 | 77 | 79 | 306 | 21 | 17 | 17 | 10”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDelstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025306+22.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
FY2024Dec 31, 2024249+23.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 2023201+33.1%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022151–Form 10-K (filed 2025-02-25) ↗

Breakdown

What makes up delstrigo (doravirine/lamivudine/tenofovir disoproxil

Cite this data

StockData. (2026). Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil ($M), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-delstrigo

See every metric in the Merck KPI table. Data updated Oct 26, 2026.